Recombinant BCG vaccine (Aeras Global TB Vaccine Foundation/ UCLA)

N/A

Report date: 2022/09/02 20:00:31

Base Information

Drug NameRecombinant BCG vaccine (Aeras Global TB Vaccine Foundation/ UCLA)
Drug Alias Namerecombinant Bacillus Calmette-Guerin 30rBCG30
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Live attenuated vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsTuberculosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Africa
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California At Los AngelesAeras
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAeras
Active IndicationsN/A
Inactive IndicationsTuberculosis

Other Information

ATC CodeN/A
Related LinksN/A